These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23456765)

  • 1. Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant.
    Xu M; Xing Y; Zhou L; Yang X; Yao W; Xiao W; Ge C; Ma Y; Yang J; Wu J; Cao R; Li T; Liu J
    Tumour Biol; 2013 Jun; 34(3):1399-408. PubMed ID: 23456765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Fixed Human Umbilical Vein Endothelial Cell Vaccine With 2 Tandem Repeats of Microbial HSP70 Peptide Epitope 407-426 As Adjuvant for Therapy of Hepatoma in Mice.
    Xu M; Zhou L; Zhang Y; Xie Z; Zhang J; Guo L; Wang C; Yang X
    J Immunother; 2015 Sep; 38(7):276-84. PubMed ID: 26261891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion with human lung cancer cells elongates the life span of human umbilical endothelial cells and enhances the anti-tumor immunity.
    Mu X; Fang C; Zhou J; Xi Y; Zhang L; Wei Y; Yi T; Wu Y; Zhao X
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):111-23. PubMed ID: 26139353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose docetaxel enhances the anti-tumour efficacy of a human umbilical vein endothelial cell vaccine.
    Zhou L; Lu M; Zhong W; Yang J; Yin Y; Li M; Li D; Zhang S; Xu M
    Eur J Pharm Sci; 2020 Jan; 142():105163. PubMed ID: 31756447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor efficacy by combination treatment with a human umbilical vein endothelial cell vaccine and a tumor cell lysate-based vaccine.
    Xu M; Zhou L; Zhang P; Lu Y; Ge C; Yao W; Xing Y; Xiao W; Dong Y; Wu J; Cao R; Li T
    Tumour Biol; 2013 Oct; 34(5):3173-82. PubMed ID: 23771850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Antitumor Efficacy of Combined Vaccine Based on the Induced HUVECs and DC-CT26 Against Colorectal Carcinoma.
    Zhang Q; Xie C; Wang D; Yang Y; Liu H; Liu K; Zhao J; Chen X; Zhang X; Yang W; Li X; Tian F; Dong Z; Lu J
    Cells; 2019 May; 8(5):. PubMed ID: 31121964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity.
    Chen XY; Zhang W; Zhang W; Wu S; Bi F; Su YJ; Tan XY; Liu JN; Zhang J
    Clin Cancer Res; 2006 Oct; 12(19):5834-40. PubMed ID: 17020991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced inhibition of murine prostatic carcinoma growth by immunization with or administration of viable human umbilical vein endothelial cells and CRM197.
    Huiyong Z; Yong L; Didier M; Yu Z; Jing F; Rongyue C; Jingjing L
    Braz J Med Biol Res; 2011 Feb; 44(2):140-8. PubMed ID: 21180889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local injection of OK432 can augment the TH1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential.
    Okamoto T; Harada M; Tamada K; Yoshida H; Ito O; Kong YY; Takenoyama M; Hirashima C; Matsuzaki G; Nomoto K
    Int J Cancer; 1997 Mar; 70(5):598-605. PubMed ID: 9052762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The concurrent administration of OK432 augments the antitumor vaccination effect with tumor cells by sustaining locally infiltrating natural killer cells.
    Kurosawa S; Harada M; Shinomiya Y; Terao H; Nomoto K
    Cancer Immunol Immunother; 1996 Sep; 43(1):31-8. PubMed ID: 8917633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sonodynamic therapy improves anti‑tumor immune effect by increasing the infiltration of CD8+ T cells and altering tumor blood vessels in murine B16F10 melanoma xenograft.
    Peng Y; Jia L; Wang S; Cao W; Zheng J
    Oncol Rep; 2018 Oct; 40(4):2163-2170. PubMed ID: 30106435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Wei Y; Kan B
    Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):118-21. PubMed ID: 11783014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luteolin as an adjuvant effectively enhances CTL anti-tumor response in B16F10 mouse model.
    Tian L; Wang S; Jiang S; Liu Z; Wan X; Yang C; Zhang L; Zheng Z; Wang B; Li L
    Int Immunopharmacol; 2021 May; 94():107441. PubMed ID: 33611060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
    Winter H; Hu HM; McClain K; Urba WJ; Fox BA
    J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of tumors with human telomerase reverse transcriptase immortalized human umbilical vein endothelial cells.
    Mu X; Sang Y; Fang C; Shao B; Yang L; Yao K; Zhao X; Gou J; Wei Y; Yi T; Wu Y; Zhao X
    Int J Oncol; 2015 Nov; 47(5):1901-11. PubMed ID: 26398907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of in vivo anti-tumor activity of human umbilical vein endothelial cell vaccines prepared by various antigen forms.
    Zhou L; Si C; Li D; Lu M; Zhong W; Xie Z; Guo L; Zhang S; Xu M
    Eur J Pharm Sci; 2018 Mar; 114():228-237. PubMed ID: 29277666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    van Elsas A; Hurwitz AA; Allison JP
    J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.